Hepatitis D surgery: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:
===Liver Transplantation===
===Liver Transplantation===
[[Liver transplant]] is indicated in patients with end-stage [[liver disease]], or [[liver failure]] secondary to [[HDV infection]], in whom treatment with [[interferon]] is not indicated.<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761  }} </ref><ref name="pmid20051970">{{cite journal| author=Wedemeyer H, Manns MP| title=Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. | journal=Nat Rev Gastroenterol Hepatol | year= 2010 | volume= 7 | issue= 1 | pages= 31-40 | pmid=20051970 | doi=10.1038/nrgastro.2009.205 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20051970  }} </ref><ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329  }} </ref> These patients usually have a good [[outcome]], with inhibition of [[HBV]] and [[HDV]] reinfection, when simultaneously treated with [[nucleoside]] and [[nucleotide]] analogues, and [[hepatitis B]] [[antibodies]].<ref name="pmid7843702">{{cite journal| author=Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF et al.| title=Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. | journal=Hepatology | year= 1995 | volume= 21 | issue= 2 | pages= 333-9 | pmid=7843702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7843702  }} </ref> However, [[HDV]] remains latent and can be detected in the new [[liver]] for several months after the [[transplant]]. Therefore prevention of [[HBV]] reinfection should be maintained, in order to simultaneously avoid resurgence of [[HDV]].<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761  }} </ref>
[[Liver transplant]] is indicated in patients with end-stage [[liver disease]], or [[liver failure]] secondary to [[HDV infection]], in whom treatment with [[interferon]] is not indicated.<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761  }} </ref><ref name="pmid20051970">{{cite journal| author=Wedemeyer H, Manns MP| title=Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. | journal=Nat Rev Gastroenterol Hepatol | year= 2010 | volume= 7 | issue= 1 | pages= 31-40 | pmid=20051970 | doi=10.1038/nrgastro.2009.205 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20051970  }} </ref><ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329  }} </ref> These patients usually have a good [[outcome]], with inhibition of [[HBV]] and [[HDV]] reinfection, when simultaneously treated with [[nucleoside]] and [[nucleotide]] analogues, and [[hepatitis B]] [[antibodies]].<ref name="pmid7843702">{{cite journal| author=Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF et al.| title=Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. | journal=Hepatology | year= 1995 | volume= 21 | issue= 2 | pages= 333-9 | pmid=7843702 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7843702  }} </ref> However, [[HDV]] remains latent and can be detected in the new [[liver]] for several months after the [[transplant]]. Therefore prevention of [[HBV]] reinfection should be maintained, in order to simultaneously avoid resurgence of [[HDV]].<ref name="pmid23242761">{{cite journal| author=Heidrich B, Manns MP, Wedemeyer H| title=Treatment options for hepatitis delta virus infection. | journal=Curr Infect Dis Rep | year= 2013 | volume= 15 | issue= 1 | pages= 31-8 | pmid=23242761 | doi=10.1007/s11908-012-0307-z | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23242761  }} </ref>
<!--
After liver transplantation, reinfection of the the new liver may be reduced by administration of HBsAg immunoglobulins, which create an en
-->


==References==
==References==

Revision as of 12:30, 13 August 2014

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D surgery

CDC on Hepatitis D surgery

Hepatitis D surgery in the news

Blogs on Hepatitis D surgery

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Overview

Treatment of hepatitis D does not involve surgery. Some procedures may be indicated in certain complications, such as ascites, in which peritoneal drainage may be performed. End-stage liver disease, liver failure secondary to HDV infection, in patients in which treatment with interferon is not indicated, and hepatocellular carcinoma may require liver transplantation.[1][2]

Surgery

The treatment of hepatitis D does not involve surgical procedures. However, some complications, such as ascites, may require interventional procedures such as peritoneal drainage.

Liver Transplantation

Liver transplant is indicated in patients with end-stage liver disease, or liver failure secondary to HDV infection, in whom treatment with interferon is not indicated.[1][2][3] These patients usually have a good outcome, with inhibition of HBV and HDV reinfection, when simultaneously treated with nucleoside and nucleotide analogues, and hepatitis B antibodies.[4] However, HDV remains latent and can be detected in the new liver for several months after the transplant. Therefore prevention of HBV reinfection should be maintained, in order to simultaneously avoid resurgence of HDV.[1]

References

  1. 1.0 1.1 1.2 Heidrich B, Manns MP, Wedemeyer H (2013). "Treatment options for hepatitis delta virus infection". Curr Infect Dis Rep. 15 (1): 31–8. doi:10.1007/s11908-012-0307-z. PMID 23242761.
  2. 2.0 2.1 Wedemeyer H, Manns MP (2010). "Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead". Nat Rev Gastroenterol Hepatol. 7 (1): 31–40. doi:10.1038/nrgastro.2009.205. PMID 20051970.
  3. Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
  4. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF; et al. (1995). "Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis". Hepatology. 21 (2): 333–9. PMID 7843702.

Template:WH Template:WS